Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans

by Katinger D, Wagner A, Luque I, Crespillo S, Conejero-Lara F, Roger M, Martin C, Mouz N, Mourao S, Farsang A, Notka F, Malcolm K, Bosquet N, Le Grand R, Moog C, Cope A, Shattock R, Lewis DJ, El Habib R
Published 2012-09-01